1Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol, 2002, 97: 2364-2370.
2Joseph F Jr, Rosenberg AJ. Breath hydrogen testing: diseased versus normal patients. J Pediatr Gastroenterol Nutr, 1988,7:787-788.
3Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syn drome. Am J Gastroenterol, 2000,95:3503-3506.
4Heller J, Sogni P, Barriere E, et al. Effects of lipopolysaccharide on TNF-a production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol, 2000,33:376-381.
5Burt AD. Cellular and molecular aspects of hepatic fibrosis. J Pathol, 1993,170:105-114.
6Wong L, Yamasaki G, Johnson RJ, et al. Induction of betaplatelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest,1994, 94:1563-1569.
7Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol, 1998,29: 836-847.
8Ikura Y, Morimoto H, Ogami M, et al. Expression of plateletderived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol, 1997,32: 496-501.
9Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci, 1997,92:103-112.
